Document is current

Article History

Received: 9 October 2020

Revised: 4 December 2020

Accepted: 11 December 2020

First Online: 2 February 2021

Ethical approval and consent to participate or publish

: Not applicable.

: Not applicable.

: Not applicable.

: We declare support from University College London Hospitals (UCLH)/UCL Comprehensive Biomedical Research Centre, UCLH Charities, National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme, Ninewells Cancer Campaign, National Health and Medical Research Council, and Cancer Research Campaign (now Cancer Research UK) for the submitted work; J.S.V. has received a research grant from Photoelectron Corp (1996–1999) and from Carl Zeiss for supporting data management at the University of Dundee (Dundee, UK, 2004–2008), and has received honorariums. J.S.V., J.S.T. and M.B.u. receive funding from HTA, NIHR, Department of Health and Social Care for some activities related to the TARGIT trials. M.B.a. was briefly on the scientific advisory board of Carl Zeiss and was paid consultancy fees before 2010. All authors received some travel support from Carl Zeiss. Carl Zeiss had no role in concept, design, analysis or writing of the manuscript.

: No specific funding was made available for this paper. The TARGIT-A trial was sponsored by University College London Hospitals (UCLH)/UCL Comprehensive Biomedical Research Centre. Funding was provided by UCLH Charities, National Institute for Health Research (NIHR) Health Technology Assessment programme (HTA 07/60/49), Ninewells Cancer Campaign, National Health and Medical Research Council, and German Federal Ministry of Education and Research (BMBF) FKZ 01ZP0508. The infrastructure of the trial operations office in London, UK was supported by core funding from Cancer Research Campaign (now Cancer Research UK) when the trial was initiated. The funding organisations had no role in concept, design, analysis or writing of the manuscript.